Nls Pharmaceutics Ag Stock Beneish M Score

NLSPW Stock  USD 0.01  0  18.18%   
This module uses fundamental data of NLS Pharmaceutics to approximate the value of its Beneish M Score. NLS Pharmaceutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out NLS Pharmaceutics Piotroski F Score and NLS Pharmaceutics Altman Z Score analysis.
  
Net Debt is likely to climb to about 772.9 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 1.4 M in 2024. At this time, NLS Pharmaceutics' ROIC is fairly stable compared to the past year. ROE is likely to climb to 1.45 in 2024, whereas Book Value Per Share is likely to drop (0.24) in 2024.
At this time, NLS Pharmaceutics' M Score is unavailable. The earnings manipulation may begin if NLS Pharmaceutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by NLS Pharmaceutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of NLS Pharmaceutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-8.09
Beneish M Score - Unavailable
Elasticity of Receivables

N/A

Focus
Asset Quality

N/A

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

0.33

Focus

NLS Pharmaceutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if NLS Pharmaceutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables10.1 K10.7 K
Notably Down
Slightly volatile
Total Assets3.3 M1.8 M
Way Up
Slightly volatile
Total Current Assets3.1 M1.8 M
Way Up
Pretty Stable
Non Current Assets Total22.4 K23.6 K
Notably Down
Pretty Stable
Selling General Administrative6.2 M5.9 M
Sufficiently Up
Slightly volatile
Total Current Liabilities4.5 M7.9 M
Way Down
Slightly volatile
Non Current Liabilities Total3.4 M2.8 M
Fairly Up
Slightly volatile
Short Term Debt1.8 M1.9 M
Notably Down
Pretty Stable
Long Term Debt268 K282.1 K
Notably Down
Slightly volatile

NLS Pharmaceutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between NLS Pharmaceutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NLS Pharmaceutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find NLS Pharmaceutics' degree of accounting gimmicks and manipulations.

About NLS Pharmaceutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

9,753.84

At this time, NLS Pharmaceutics' Depreciation And Amortization is fairly stable compared to the past year.

NLS Pharmaceutics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as NLS Pharmaceutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables75.4K61.2K38.6K41.2K10.7K10.1K
Total Assets696.4K1.2M5.8M9.3M1.8M3.3M
Total Current Assets381.7K196.7K5.7M9.2M1.8M3.1M
Non Current Assets Total314.7K1.0M41.6K30.2K23.6K22.4K
Depreciation And Amortization4.2M2.3M10.1K11.4K10.3K9.8K
Selling General Administrative3.3M2.2K5.9K6.5K5.9M6.2M
Total Current Liabilities4.0M7.2M2.4M3.4M7.9M4.5M
Non Current Liabilities Total2.8M3.0M2.8M2.6M2.8M3.4M
Net Debt621.9K2.0M(5.4M)(8.9M)736.1K772.9K
Short Term Debt690.1K1.8M2.5B1.6M1.9M1.8M
Operating Income(4.2M)(2.3M)(11.9M)(15.5M)(11.8M)(12.4M)
Total Cash From Operating Activities(190.0K)(729.4K)(14.9M)(13.9M)(9.7M)(10.2M)

About NLS Pharmaceutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.